Skip to main content

News

The latest news, stories, and updates from the Children's Tumor Foundation.

 

Filter

A person stands with arms crossed next to text announcing their joining CureAge Therapeutics from the Children's Tumor Foundation. Logos of both organizations are displayed.
Collaborations & PartnershipsGlobalPress Release

Children’s Tumor Foundation’s Montse Montaner Joins CureAge Therapeutics

Seasoned international advisor will serve on the board of CureAge Therapeutics The Children's Tumor Foundation…
Children's Tumor Foundation logo on the left and Rare Disease Day logo with February 28 date on the right.
AdvocacyAwarenessFeaturedFeatured EUPharma

From NF to the World: Rare Disease Day and the Race for Faster Treatments

This has been a February to remember! In just a few weeks, a new drug…
Collaborations & PartnershipsFeaturedFeatured EUNF1PharmaPress ReleaseScience & Research

Healx Announces First Patient Dosed in Phase 2 Trial Evaluating HLX-1502 for the Treatment of NF1

Healx has dosed the first patient in its Phase 2 trial for HLX-1502 - the…
Tri-fold brochure for Children's Tumor Foundation Europe, detailing NF information, mission, and contact details. Features images of smiling people and foundation's logo.
Featured EU

CTF Europe Brochure in Multiple Languages

We are pleased to share our new trifold brochure about CTF Europe, now available in…
Three people smiling and posing in front of a banner for the 2024 Global Conference, held in Brussels from June 20-25, 2024.
Collaborations & PartnershipsFeaturedFeatured EUNF1PharmaPress ReleaseScience & Research

CureAge Therapeutics Launches to Advance Genetic Therapies for Neurofibromatosis

Children’s Tumor Foundation and Deep Science Ventures Spearhead New Biotech to Develop Curative Treatments for…
Child cheering beside text: "IT'S A GO! FDA approves drug for children and adults with NF1." Website: ctf.org.
NF1PharmaScience & ResearchTop StoryTop Story EU

IT’S A GO! NF’s NEXT BIG WIN!

Today, we make history... again! The FDA has officially approved Gomekli (mirdametinib) - the second-ever…
Awards & GrantsFeaturedFeatured EUNF1Science & Research

Young Investigator: Q&A with Alex Dyson about NF1 and brain mechanisms

The Young Investigator Award (YIA) provides two-year salary support to early-career NF researchers to help…
Podcast cover with two speakers, Kate Kelts and Mark Oppenheimer, titled "Understanding and Combating Neurofibromatosis." Logos of Community Foundation and Business RadioX are visible.
AwarenessFeaturedFeatured EU

Good2Give Podcast: Understanding and Combating NF: Insights from the Children’s Tumor Foundation

Click here to jump to the podcast transcript.  An episode of the Good2Give Podcast, hosted…
Four people wearing green shirts hold "Make NF Visible" signs, standing in a room with photos and text on the walls.
Awards & GrantsFeaturedFeatured EUNF2-SWN

Making NF Visible in Germany

The Children’s Tumor Foundation is proud to provide funding to Lars Björn Riecken, PhD, and…
Children's Tumor Foundation logo with the text "Ending NF Through Research" and "Cure NF with Jack" next to a four-leaf clover on a blue background.
Collaborations & PartnershipsFeatured EUNF1Press ReleaseScience & ResearchTop Story

Children’s Tumor Foundation and CureNFwithJack Announce Next Phase of the Groundbreaking Biomarker Project for NF1 Tumor Detection

Collaboration Accelerates the Development of a Non-Invasive Blood Test to Identify and Track Cancerous Tumors…
A gloved hand uses a pipette to add liquid to a multiwell plate in a laboratory setting.
Awards & GrantsFeaturedFeatured EU

CTF Clinical Research Awards

At the Children's Tumor Foundation (CTF), our commitment to advancing neurofibromatosis and schwannomatosis (NF) research…
Five people are shown under the title "2024 Drug Discovery Initiative Awardees" on a colorful background.
Awards & GrantsFeaturedFeatured EU

2024 Drug Discovery Initiative Awardees

The Children’s Tumor Foundation is pleased to announce a significant investment of more than $995,000…